National Drug Code (NDC) for Healthcare Providers

NUS Medicine
8 followers
1 Video View·Dec 25, 2024
Hi, everyone. Today's webinar is titled FDA Drug Topics, National Drug Code,
NDC for Healthcare Providers. My name is Dr. Cara Burke, a pharmacist and team leader in
the Division of Drug Information. I would like to welcome you to this educational activity sponsored
by the FDA Center for Drug Evaluation and Research, Office of Communications, Division of
Drug Information. We thank you and appreciate your patience as we continue to offer these CE
courses completely virtual. If you experience any technical difficulties, please email us
at ddiwebinars at fda.hhs.gov for direct assistance. Before I introduce our speaker,
I have a few housekeeping remarks. All faculty are expected to use generic names. If trade names are
used, those of several companies should be used rather than only that of a single supporting
company. Unapproved use disclosure. CE faculty speakers are required to disclose to the attendees
when products or procedures being discussed are off-label, unlabeled, not FDA approved,
and any limitations on the information that is presented. Disclosure. The faculties,
planning committee members, and the FDA CE consultation and accreditation team have nothing
to disclose. We hope you will enjoy meeting our presenter today. Dr. Leila Raju Esfanyari is the
branch chief for the Drug Registration and Listing Branch in the Office of Unapproved Drugs and
Labeling Compliance. She started her FDA career with Drug Registration and Listing, or DRLS, in 2008
and later helped create the DRLS compliance program in 2015. She earned her PharmD degree
from Tehran University School of Medical Science in Iran in 1996 and has a Certificate Degree
in American Course on Drug Development and Regulatory Sciences from the University of
California, San Francisco. She has worked in retail pharmacy and hospital settings prior to joining
the federal government. She's a subject matter expert in data integrity compliance and NDC.
Now, please give a warm online welcome to Dr. Raju Esfanyari.
Thank you, Dr. Burke, for the introduction. It's always a pleasure to work with all our
amazing colleagues in the Division of Drug Information, CDER. Hello, everyone, and thank
you for joining the FDA Drug Topics Series to learn more about the National Drug Code or the NDC.
I hope whether you are familiar with the NDC on your day-to-day work or not, you walk away from
this presentation learning something new. As mentioned, we are offering one CE credit
once you complete this presentation, and as part of the process during this presentation,
we will discuss the history of NDC and its assignment, learn about NDC formats and its
placement on drug labels, what to do if you find an incorrect data on FDA publications,
and get a sense of what may be coming in the future. To begin, let's try to read this statement.
This is a pharmacist's way of saying that humans are smarter than computer systems,
so you are all smarter than computer systems. It shows how important identifiers really are.
Scanning an incorrect barcode can return the wrong drug even if humans can tell the difference
using additional information at their disposal. So, digital identifiers are typically a string
of numeric or alphanumeric characters that uniquely identify a product or a person in
these examples. A couple of day-to-day examples are social security numbers which identify
John Doe, for example. It is a numeric identifier divided by hyphens, as you see in the picture,
or a VIN number that identifies a certain car and is a longer string with alphanumeric characters
in this example. Similar to cars and humans, drugs are assigned unique identifiers,
such as national drug code in the U.S. and drug identification number in Canada.
Identifiers can be global or regional. The global ones aim typically for global harmonization,
and the regional ones are used in one geographical region that uses specific digital systems.
In the United States, drugs are uniquely identified by the national drug code, or NDC.
NDC is a numeric code divided by hyphens. It is 10 digits and consists of three segments.
The labeller code, which is assigned by FDA and identifies the entity manufacturing or distributing
the drug. The product code, which is proposed by the labeller and identifies a specific drug.
And the package code, which is also proposed by the labeller and identifies a package size
or type of that specific drug. As you see in this example, you see an NDC in a 4-4-2 format.
The labeller code is assigned to XYZ Pharma. It is assigned by FDA. The product code identifies
drug ABC 20 milligram tablet, and it's proposed by XYZ Pharma or the entity that submits the
listing for XYZ Pharma. And the package code identifies a bottle of 100 for drug ABC 20
milligram tablets. And again, proposed by XYZ Pharma or its representative. NDC currently
exists in three different formats, the 4-4-2, the 5-3-2, and the 5-4-1. This is what you currently
find on a drug label that includes an NDC. Once the company manufacturing or distributing the drug
lists the drug for the first time and proposes a certain format, its NDC format for all its drug
listing under that labeller code remains the same format and cannot change. At the same time,
the NDC entered for billing and maintained in some databases outside of FDA at a leading zero
to the short segment to create a one format NDC. This is called the 5-4-2. This format was later
mentioned for the first time in a regulation in the Health Insurance Portability and Accountability
Act or HIPAA. As mentioned, the FDA NDC 10 is converted to the HIPAA standard NDC 11 by adding
a leading zero to the short segment. It can get more complicated when the HIPAA standard NDC 11
is converted back to the official NDC, especially if the database maintains and stores the 11-digit
NDC without the hyphens. As you see in this example provided on the slide, a HIPAA NDC 11
can be potentially translated to three different NDCs if the hyphens are not included. In healthcare,
NDC is widely used in different areas. A physician or nurse practitioner prescribing a medication for
a patient. A pharmacist or pharmacy technician filling the physician order who is actively using
NDC to fulfill the physician order, dispense the medication, and process medical billing.
Insurance industry and Medicare and Medicaid programs require NDC for accurate reimbursement.
In clinics, hospitals, and pharmacies, NDCs are directly used for ordering and inventory
management. Automated systems in these settings often check NDCs to check inventory and restock
drugs. NDCs are used extensively to ensure drug distribution and supply chain security to track
the flow of drugs through the supply chain. The NDC ensures that drugs are accurately tracked
from the manufacturer to the point of sale. In other programs, it is used in drug importation,
recalls, and effectively reporting adverse events and safety concerns to the agency.
It is used by industry, a whole range of government agencies, research, and academia.
In short, NDC is a critical element in managing healthcare in the United States.
But where does that drug data including NDC actually come from? Drug manufacturers that
are in the United States and manufacture drugs for commercial distribution or foreign
drug manufacturers that import or offer for import drugs into the United States are required to
register as a drug establishment with the FDA and submit a list of each and every drug they
manufacture for commercial distribution in the United States. As part of the data required for
this drug listing submission, drug manufacturers are required to propose an NDC that includes
all package code variations. The inclusion of NDC in a drug listing submission to FDA
was enacted through the Drug Listing Act in 1972. In fact, let's take a history walk down the NDC
road. There is a lot of information on this slide, and I will try my best to expand on each here.
First, in 1969, NDC started as voluntary reporting and was in a 3-4-2 format.
Very quickly, the agency realized that a three-digit labeler code were run out very quickly.
So, with the Drug Listing Act of 1972, NDC became a 4-4-2 format and was mandated for
drug listing submissions to FDA via paper forms. Later, when FDA ran out of the 4-digit labeler
codes, it started assigning 5-digit labeler codes. And in order to keep the NDC at 10 digits,
it created the new formats, the 5-4-1 and the 5-3-2. In 1974, the Uniform Grocery Code Council,
or UGCC, introduced 12-digit UPC and barcodes. The Omnibus Budget Reconciliation Act of 1990
required an NDC to build drugs for Medicaid paid programs, and in 1996, HIPAA adopted the
11-digit format already used by the payer industry in an attempt to standardize various NDC formats.
In 2004, the Barcode Rule required linear barcode on all drugs with an effective date of 2006.
The Food and Drug Administration Amendment Act, or FDAA, of 2007 developed the Standard
Numerical Identifier to help secure the drug supply chain by identifying, authenticating,
and tracking prescription drugs. The term Standardized Numerical Identifier means a
set of numbers or characters used to uniquely identify each package or homogeneous case
that is composed of the national drug code that corresponds to the specific product,
combined with a unique alphanumeric serial number of up to 20 characters.
In 2009, FDA started the Electronic Registration and Listing Submission, including NDC,
and in June of 2009, FDA stopped accepting the old paper forms. Drug Supply Chain Security Act
passed in 2013, which required the 2D matrix barcode to trace prescription drugs. In 2016,
the Regulations for Establishment Registration and Drug Listing Requirements under 21 Code of
Federal Regulations, Part 207, was revised. One big revision was that an NDC previously
assigned to a different drug cannot be reused. Prior to 2016, firms were able to reuse an NDC
previously assigned to a drug five years after its discontinuation. But with the effective date
of August 2017, that practice stopped and firms were not able to reuse an NDC any longer,
unless the exact same drug was introduced back in the market after it was discontinued.
Another revision was that the NDC changed from an alphanumeric code to a numeric code
based on safety concerns reported to FDA. At the same time, other NDC provisions remained the same.
That meant once the agency ran out of five-digit labeler codes, it would start assigning six-digit
labeler codes. As a result, FDA held a public hearing in 2018 to gather information and
concerns over this upcoming change and propose the revision to the NDC regulations in 2022.
Most drug labels include an NDC. The NDC appears on the upper part of the drug label
and includes the prefix NDC. The inclusion of NDC on drug label is requested but not required
per labeling requirements. NDC is typically included on prescription drug label
or principal display panel for identification and billing, but it is required to be included
in the health supply section of the prescription drug labeling anyway. NDC is also required to be
part of the barcode and barcode is required to be included in the drug label. So even if you
don't see a human readable format NDC on a drug's principal display panel, the NDC would be embedded
in the barcode. For this prescription drug label, the NDC is printed on the drug label as you can
see on the upper left side and is included in the barcode. This prescription includes a linear barcode
and a 2D data matrix barcode. The NDC can be harvested from the linear barcode
if it was also not printed on the label. Scanning machines used to scan a drug label are able to read
the NDC within the barcode, both the linear and the 2D data matrix barcodes. As you see on the
right side on the slide, in section 16 of a prescription drug labeling within the package insert,
all NDCs and packaging description associated with the drug must be included. So things are
a bit different for OTC drug label. Could be a little different for an OTC drug label. For example,
did you know antiseptic mouthwashes, anti-dandruff shampoos, and fluoride toothpaste are typically
drugs? You may not find an NDC in human readable format on their label for these products in your
retail pharmacy or grocery store, but you can try to find them embedded in the barcode as shown here
on this slide. Generally speaking, lack of NDC on a product label does not mean it is not a drug.
All drugs in U.S. commercial distribution must be listed with FDA, and NDC, as mentioned,
is a required data element for drug listing. This means a listed drug will be assigned an NDC,
but the assigned NDC may not be included in a human readable format on its label.
NDC must be assigned to all drugs, including human or animal, prescription or OTC,
and approved or unapproved drugs. Additionally, inclusion of NDC on a product label does not
mean the product is a drug or it is legally marketed in the United States. The hint is in
the name, the National Drug Code. It should not be assigned to any product that is not a drug.
That includes dietary supplements and medical devices. In fact, a product may be deemed to be
misbranded if an NDC is included on its labeling, but the product is not a drug.
Under FDA's 21 Code of Federal Regulations, part 20777B, any representation that creates the
impression that a drug is approved or is legally marketable because it appears in our database of
drugs, has been assigned or displays an NDC, or the establishment has been assigned an establishment
registration number or unique facility identifier is misleading and constitutes misbranding.
In other words, registration and listing with FDA does not mean that FDA has made a determination
that your product is a drug or you're allowed to manufacture or distribute that drug in the U.S.
Part of the NDC regulations describes conditions under which the NDC assigned to a drug must
change. If a drug's established name or proprietary name changes or there are any
changes to the active ingredient or ingredients, strength or strengths, dosage form, the product
code assigned to the drug must change. When a drug status switches from a prescription to OTC,
a new NDC is required to be assigned that is different at the product code level.
Additionally, if any physical characteristic of a drug changes, a new product code is required to
be assigned. For example, a tablet with a new scoring, a new shape, a new color, or an elixir
with a different taste cannot be assigned the same product code. A package code must be different
for different packaging sizes or types of a specific drug. For example,
bottles of 30 and 100 counts of a drug or a plastic and glass container of an IV drug
cannot be assigned the same package code. If the NDC is not assigned correctly,
it can create several concerns. For example, if different strengths of an injectable pen
are assigned the same product code, it creates major safety concerns because patients can be
dispensed or administered the wrong dose. A change in the product code segment,
when physical characteristics of the drug change, will increase patient compliance because the
pharmacist is able to identify the change and alert the patient at the time of dispensing.
If you ever use the great services that Poison Control Centers provide, you are asked to provide
those physical characteristics to identify the drug. Poison Control Centers use the description
of those characteristics, amongst other information, to correctly identify the drug.
On the other hand, if the package code is not assigned correctly, insurance may be billed for
the wrong quantity, which can lead to incorrect billing and reimbursement issues. The listing data,
including the NDC, is provided online in several publications. The first one is the NDC directory
that is maintained by FDA. It is updated daily on working weekdays from listing submissions to the
agency. It includes finished and unfinished human drugs in two separate sections, but it does not
include labeling. Daily Med includes labeling for human and animal drugs. It is managed by
the National Institute of Health, but it receives the data from the same listing submissions to FDA
daily, again on working weekdays. It is worth mentioning that there are other FDA and government
publications that use the listing data to display labeling, including the NDC. One example is the
FDA labeled repository, which is not maintained by our group. Outside of the government, drug data
banks also use this information in addition to other resources to publish their data. So,
occasionally and unfortunately, you will find errors in these publications. These are errors
introduced at the time of listing submissions by firms. Although FDA has put in place numerous
automated validation procedures, which prevent certain errors, it cannot stop all errors from
submission. For example, a computer system can detect and validate the NDC length and format
automatically. It can also detect the submission of a JPIC file for the principal display panel as
a part of required labeling submission. But currently, it cannot validate if the JPIC file
is actually a representation of the listed drug label. Maybe with the AI help in the future,
we can actually detect that part also automatically in the future. But as of now,
you may find, very hopefully rarely, labels that do not represent a listed drug, and that is a
major concern for FDA. If you see any errors in any of our online publications, for example,
a labeling issue, if you are holding a roundtable, for example, but DailyMed includes a caplet,
you can contact us. You can contact our group at our general email address at edrls
at fda.hhs.gov and provide the information. According to current regulations, FDA will
start assigning six-digit labeler codes once it runs out of five-digit labeler codes.
It is estimated that we may have 10 to 15 years till then. As we experience with the COVID pandemic,
we run out actually faster than 15 years. That's why we don't have an exact number.
If nothing changes, this means that two new formats will be introduced, the 632 and the 641.
There will be an FDA NDC 10 and FDA NDC 11, expanding FDA NDCs to five formats. In addition
to HIPAA NDC 11 and anything else that might be adopted by HIPAA and others outside FDA.
To address this issue, FDA published a federal register notice and suggested four possible
options. Option A, maintaining current practice without any modification. Basically, we wait
to run out of five-digit labeler codes and start assigning six-digit labeler codes and have
five different FDA NDC formats. Option B was the same as option A, but transitioning on a specific
date in the future to add more certainty. Option C was for FDA to adopt the 11-digit HIPAA format
and transition to 12-digits later once we run out of five-digit labeler codes.
Option D was harmonizing NDC by adopting a 12-digit 642 format. A public hearing was held
on November 5, 2018, where several stakeholders presented to the audience and an FDA panel.
Based on the presentations and comments, FDA published a proposed rule on July 22, 2022,
proposing option D to move to a 12-digit one-format NDC in the future and is currently
working on finalizing the rule. As for the takeaway, NDC is the major drug identifier
in the United States. It is proposed by firms at the time of drug listing
and gets assigned by FDA. As a result, since all drugs in U.S. commercial distribution
must be listed with FDA, they all must be assigned an NDC. But that doesn't mean that
FDA has made a determination that the product is a drug or is legally marketed. You may find
NDC on a drugs principle display panel in a human-readable format or not, and NDC length
and format may change in the future. I provided a list of some of the resources that were mentioned
in this presentation, and you can find them by clicking on each of the links provided here.
If you have any questions, feel free to reach out to me or our general email address, which is
edrls at fda.hhs.gov, which we have several wonderful colleagues that are available to
assist you with your registration and listing questions or with NDC assignment or NDC questions.
To close, correct NDC assignment and use is essential to patient safety and healthcare
administration. Follow FDA announcements to learn about its future format. Thank you for
your participation and attention. All right. Thank you so much, Dr. Raju Aspanyari.
This concludes the presentation portion of our webinar. First question, what are international
NDC requirements for manufacturers outside of U.S. or online pharmacies that import medications?
First of all, pharmacies, the practice of pharmacy, and I have to point out that some
practices incorrectly refer themselves as a pharmacy, but let's say in this case,
this is an actual pharmacy, and if they are not manufacturing any drugs, they are not subject
to registration and listing requirements themselves. If you are importing drugs into U.S.,
however, that drug needs to be listed with FDA, and whoever manufactures it
has to be registered with FDA, whether inside or outside of the U.S. So you are probably,
if you are an online pharmacy, you are probably the importer of record for that particular drug,
and the drug has to be registered and listed. There are certain
importation requirements for drugs which we cannot get into in this presentation because
it's outside of this discussion, but you can definitely look into that, but in terms of the
NDC requirements, in terms of the registration and listing requirements, the same thing applies,
maybe not to you, but to the company that manufactures the drug and distributes it here
in the U.S. Thank you so much, Leila. The next question, what is the benefit for some products
where the 25-count box has one NDC and then the individual vials have a different NDC?
So based on the regulations, the NDC assigned to, let's say you are talking about a box that
has 25 vials in it, right? The box itself is a different package size and type. So you are
looking at a box of 25 vials. The box has to have a different package code, and each individual
vial has to have a different NDC package code. So when you are, for example, dispensing a vial,
there is a difference between what you are actually dispensing when you use the package
code for the box or for the vial, and so therefore it's billed and dispensed correctly.
Thank you, Leila. We have a lot of good ones coming in. I'm trying to keep up. All right,
next one. You said FDA is working on standardizing the 642 format. Would this mean we would
have only one single format? This would be ideal.
So I want to emphasize that what we discussed here is about a proposed rule. So the way
regulations work is that the federal agencies, in this case, we saw an issue. We had a public
hearing. We heard from stakeholders, and we then published a proposed rule. So there has to be a
proposed rule where people comment on, and that happened in 2022. We received the comments. We
are working on finalizing it. So a rule is not going to be in effect until it's finalized,
and it doesn't mean it will be finalized exactly the same way it was proposed because, again,
the federal agencies, again, have to open the docket for comments, receive the comments,
and respond to those comments, and if needed, revise the proposal in the final rule. So
we're working on it. We're hoping to finalize it soon, but once finalized, then we will know
exactly what's going to happen. At this point, as proposed, yes, that is the intention. That
was the intention at the time of proposal, that we move at least FDA moves to the 6421 format,
NDC, and whether or not if others also follow, as I said, you know, the payer industry,
for example, is using an 11-digit NDC right now. That is, like, up to the payer industry,
whether if they move also to the same exact standard, but the proposal is that we move to a
6421 format currently. So stay tuned for the final rule. That's all I can say.
Thank you so much, Leila. The next question, at what point in the approval process is the NDC
published in the database? So that's a good question, and it brings up a good point,
actually, because so we mentioned, you know, the NDC is required to be assigned to all drugs,
right? So, for example, OTCs are not even some OTC drugs are not or most of OTC drugs are not
subject to drug approval, right? But they still have to be listed with FDA. They still have to
be assigned an NDC. So for approved drugs that go through the FDA approval process, as you know,
there are several different steps, and in final phases, the labeling actually is developed and
approved. As part of labeling submission to FDA, applicants typically include an NDC or at least a
placeholder for the NDC under drug label. What is very important to keep in mind is that the NDC
itself is not reviewed and approved during the drug approval process. So that's a very
important factor that all applicants have to bear in mind. The NDC placement is reviewed on a drug
label or in the house supplied section. If you have a prescription drug application, you know,
the packaging configurations, for example, are being reviewed and approved, but the NDC itself
in terms of if it is the correct length, if it is the correct format, if it has not been reused,
you know, from a previously listed drug, as we mentioned, those are not actually being looked at.
So what we try to recommend to applicants is that they do check with our group if they have
any NDC questions during the drug approval process. And again, that email address is
edrls.fda.hhs.gov. Or not to really move away from the subject here, but
there is also an NDC reservation option available for drugs that are in development and are not
approved and ready for launch yet. So that submission to FDA includes very minimal
requirements in terms of what kind of data you need because the drug is not approved yet. So
you may not have, for example, your proprietary name approved yet. So it includes just very few
data elements. And you basically reserve the NDC to make sure that initial validation for the NDC
passes. And so therefore, you can actually use that NDC to then list your drug after approval.
And once you start commercial distribution. And that NDC reservation document can later on
develop and further revise to actually change to a listing submission, which then takes care of
your listing requirements and labeling submission requirements after approval.
Thank you, Leila. All right. Next question. Do compounded drugs have NDC numbers?
So compounded drugs is a completely different area. It's a whole different office that
work actually on compounded drugs. So I don't want to really get into the requirements for
compounded drugs, but they can be assigned NDCs. From my understanding,
they do not need to provide it to FDA at the time of their reporting. But that's a completely
different area. And there is an office that oversees that. Thank you, Leila. All right.
So let's do a couple more. Can you go over when does the NDC format change again?
We don't know yet. Stay tuned if it does. So again, it's a proposed rule and it's being
finalized. And we will publish the information as soon as actually it is finalized. And so therefore
you have a lot more clarity on what to expect. And I will also add for those of you that are
interested in actually receiving that information is that once an agency is going to publish a rule,
we have to actually publish a notice in a Federal Register website. So if you are interested in
getting those information or notification, you have to sign up at federalregister.gov,
which includes Federal Register notice email notifications, which you can subscribe to.
Thanks, Leila. That was the second question. The next question coming in,
how will I know when the NDC final rule is published? So again, make sure you are
going on the Federal Register and getting notifications like Leila just said. Okay.
Maybe two more questions. Should we report a drug that we cannot find any records for
on the NDC directory? Absolutely. Yes. Yeah. Because we do have
ways to find those products. A drug that is in the U.S. commercial distribution without being listed
with FDA can potentially be misbranded. So if you have a drug in your possession, you are dispensed
the medication, you have it in your possession and you don't find a drug listing for it on any of the
publications mentioned in this presentation, please reach out to us and report it.
And we will look into it. Okay. We'll take our final question.
Since we're almost at the two o'clock mark, if a drug is discontinued from the market,
can its NDC be assigned to another drug? No. So as mentioned with the 2016 registration
and listing regulation that was revised at the time, it went into effect in 2017. And
unlike previous practices, because it was allowed under the old regulations,
with the new one, the reuse of the NDC for a different drug is no longer allowed because
it created a lot of issues. Once an NDC is out there assigned to a certain drug,
that information can remain in the downstream databases forever. And there is no way for FDA to
alert those outside of FDA databases or correct them. And therefore to avoid medication errors,
FDA stopped that practice. On this, again, as I mentioned, if a drug is discontinued
and comes back in the market exactly the same way as it was, then the same NDC has to be assigned.
But if not, it cannot be assigned to any other drug ever. All right. Thank you so much, Layla.
That was a great presentation. Very informational. If you have questions, please email them to our
druginfo.fda.hhs.gov for assistance. If you need more CEs for your license renewals this year,
please check out our list of home study CE webinars on our homepage, www.fda.gov.ddiwebinars.
This concludes our activity for today. The FDA appreciates your participation in this webinar,
and we hope that you will join us again in the future. Thank you all for attending,
and please stay safe and healthy at the start of this holiday season. Thanks, everyone. Take care.
